Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

BackgroundIndividualized drug response prediction is vital for achieving personalized treatment of cancer and moving precision medicine forward. Large-scale multi-omics profiles provide unprecedented opportunities for precision cancer therapy.MethodsIn this study, we propose a pipeline to identify subpathway signatures for anticancer drug response of individuals by integrating the comprehensive contributions of multiple genetic and epigenetic (gene expression, copy number variation and DNA methylation) alterations.ResultsTotally, 46 subpathway signatures associated with individual responses to different anticancer drugs were identified based on five cancer-drug response datasets. We have validated the reliability of subpathway signatures in two independent datasets. Furthermore, we also demonstrated these multi-omics subpathway signatures could significantly improve the performance of anticancer drug response prediction. In-depth analysis of these 46 subpathway signatures uncovered the essential roles of three omics types and the functional associations underlying different anticancer drug responses. Patient stratification based on subpathway signatures involved in anticancer drug response identified subtypes with different clinical outcomes, implying their potential roles as prognostic biomarkers. In addition, a landscape of subpathways associated with cellular responses to 191 anticancer drugs from CellMiner was provided and the mechanism similarity of drug action was accurately unclosed based on these subpathways. Finally, we constructed a user-friendly web interface-CancerDAP (http://bio-bigdata.hrbmu.edu.cn/CancerDAP/) available to explore 2751 subpathways relevant with 191 anticancer drugs response.ConclusionsTaken together, our study identified and systematically characterized subpathway signatures for individualized anticancer drug response prediction, which may promote the precise treatment of cancer and the study for molecular mechanisms of drug actions.

[1]  Michael T. Zimmermann,et al.  Predict drug sensitivity of cancer cells with pathway activity inference , 2019, BMC Medical Genomics.

[2]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[3]  Wei Liu,et al.  Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells , 2017, Scientific Reports.

[4]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[5]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[6]  C. So,et al.  β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. , 2010, Cancer cell.

[7]  Jeffrey W. Clark,et al.  Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. , 2015, Cancer discovery.

[8]  R. Antonetti,et al.  Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  Haibo He,et al.  Learning from Imbalanced Data , 2009, IEEE Transactions on Knowledge and Data Engineering.

[10]  Ao Li,et al.  A novel approach for drug response prediction in cancer cell lines via network representation learning , 2018, Bioinform..

[11]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[12]  Rahul Kumar,et al.  CancerDR: Cancer Drug Resistance Database , 2013, Scientific Reports.

[13]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[14]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[15]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[16]  M. Loh,et al.  MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. , 2015, Blood.

[17]  Heidi L. Rehm,et al.  Building the foundation for genomics in precision medicine , 2015, Nature.

[18]  A. Florea,et al.  Targeting Intracellular Calcium Signaling ([Ca2+]i) to Overcome Acquired Multidrug Resistance of Cancer Cells: A Mini-Overview , 2017, Cancers.

[19]  Andrew J Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[20]  Xiaoxiao Sun,et al.  Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment , 2015, Acta Pharmacologica Sinica.

[21]  Andrew C. Pawlowski,et al.  The Comprehensive Antibiotic Resistance Database , 2013, Antimicrobial Agents and Chemotherapy.

[22]  N. Cox,et al.  Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.

[23]  Gokhan Yildiz.  Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells , 2018, Oncology letters.

[24]  J. M. Bradshaw,et al.  Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma , 2018, Leukemia.

[25]  Julio Saez-Rodriguez,et al.  The germline genetic component of drug sensitivity in cancer cell lines , 2018, Nature Communications.

[26]  H. Hong,et al.  Drug Repositioning Through Network Pharmacology. , 2016, Current topics in medicinal chemistry.

[27]  Fan Zhang,et al.  A network medicine approach to build a comprehensive atlas for the prognosis of human cancer , 2016, Briefings Bioinform..

[28]  Huilong Duan,et al.  Measure clinical drug-drug similarity using Electronic Medical Records , 2019, Int. J. Medical Informatics.

[29]  Xiaoqi Zheng,et al.  A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia , 2016, Scientific Reports.

[30]  E. Gamazon,et al.  Copy number polymorphisms and anticancer pharmacogenomics , 2011, Genome Biology.

[31]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[32]  Stephen L. Abrams,et al.  The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. , 2010, Cell cycle.

[33]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[34]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[35]  Laurent Excoffier,et al.  Detecting gene subnetworks under selection in biological pathways , 2017, bioRxiv.

[36]  X-P Chen,et al.  DNA methylation and personalized medicine , 2014, Journal of clinical pharmacy and therapeutics.

[37]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[38]  Cassandra Willyard.  Copy number variations' effect on drug response still overlooked , 2015, Nature Medicine.

[39]  William C Reinhold,et al.  CellMiner: a relational database and query tool for the NCI-60 cancer cell lines , 2009, BMC Genomics.

[40]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[41]  Bertram Klinger,et al.  Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. , 2017, Cancer research.

[42]  J. Castle,et al.  expression data: the tissue distribution of human pathways , 2006 .

[43]  Li Wang,et al.  Cooperative genomic alteration network reveals molecular classification across 12 major cancer types , 2016, Nucleic acids research.

[44]  miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway , 2015, Molecular Cancer.

[45]  Jin Gu,et al.  Evaluating the molecule-based prediction of clinical drug responses in cancer , 2016, Bioinform..

[46]  Xiaoyan Liu,et al.  Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy. , 2016, Current drug targets.

[47]  Lang Li,et al.  Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma , 2019, BMC Medical Genomics.

[48]  Tero Aittokallio,et al.  Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization , 2016, Bioinform..

[49]  Xin Zeng,et al.  Inhibition of Wnt/β‐catenin signaling downregulates P‐glycoprotein and reverses multi‐drug resistance of cholangiocarcinoma , 2013, Cancer science.

[50]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[51]  I. Sagap,et al.  Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal Cancer , 2017, Front. Pharmacol..

[52]  Chunquan Li,et al.  SubpathwayMiner: a software package for flexible identification of pathways , 2009, Nucleic acids research.

[53]  Min Pan,et al.  A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers , 2012, Genome research.

[54]  Jill U. Adams,et al.  Genetics: Big hopes for big data , 2015, Nature.

[55]  Isaac S Kohane,et al.  Ten things we have to do to achieve precision medicine , 2015, Science.

[56]  Xia Li,et al.  A sub-pathway-based approach for identifying drug response principal network , 2011, Bioinform..

[57]  Qianlan Yao,et al.  Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways , 2013, Nucleic acids research.

[58]  Martin Ester,et al.  Optimally discriminative subnetwork markers predict response to chemotherapy , 2011, Bioinform..

[59]  Jing Xiao,et al.  A comprehensive overview of oncogenic pathways in human cancer , 2019, Briefings Bioinform..

[60]  Pan Zhang,et al.  Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data , 2016, Briefings Bioinform..

[61]  Yibo Wu,et al.  GOSemSim: an R package for measuring semantic similarity among GO terms and gene products , 2010, Bioinform..

[62]  Andrew E. Teschendorff,et al.  Tissue-independent and tissue-specific patterns of DNA methylation alteration in cancer , 2016, Epigenetics & Chromatin.

[63]  Nengjun Yi,et al.  Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression , 2018, BMC Cancer.

[64]  P. Bork,et al.  GEAR: A database of Genomic Elements Associated with drug Resistance , 2017, Scientific Reports.

[65]  Howard L McLeod,et al.  Copy number variants in pharmacogenetic genes. , 2011, Trends in molecular medicine.

[66]  Mark A. Rubin,et al.  Health: Make precision medicine work for cancer care , 2015, Nature.